<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451698</url>
  </required_header>
  <id_info>
    <org_study_id>CHW 04/161</org_study_id>
    <nct_id>NCT00451698</nct_id>
  </id_info>
  <brief_title>Erythropoietin and Pediatric Cardiac Surgery</brief_title>
  <acronym>EPO</acronym>
  <official_title>Erythropoietin and Pediatric Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital and Health System Foundation, Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lack of bloodflow to the heart and brain when the heart is stopped during heart surgery can
      cause damage to those organs. We hypothesize that a single dose of erythropoietin prior to
      the heart bypass portion of surgery may protect the infant human heart and brain from injury.

      This randomized clinical trial will involve 120 children, age 6 weeks to 18 years, requiring
      heart bypass surgery for congenital heart defects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lack of bloodflow to the heart and brain when the heart is stopped during heart surgery can
      cause damage to those organs. A medicine already used in humans, erythropoietin, may protect
      the heart and brain of children born with heart defects during their surgical repair. In a
      rabbit model, erythropoietin did protect the hearts. We hypothesize that a single dose of
      erythropoietin prior to the heart bypass portion of surgery may protect the infant human
      heart and brain from injury.

      For this randomized control trial, 120 children, age 6 weeks to 18 years, requiring heart
      bypass surgery for congenital heart defects, will be divided into four groups. Two groups
      will be children whose usual blood oxygen level is low because of their heart defect; the
      other two will be children with normal blood oxygen levels. Each child will be randomized to
      receive either erythropoietin or placebo 15 minutes prior to stopping the heart during their
      surgery.

      Erythropoietin's protective function will be measured after surgery by: (1) amount of
      medication required to support heart function, (2) how well the heart pumps blood as seen by
      echocardiogram, (3) levels of chemicals produced by the body when heart or brain tissue
      injury occurs, (4) urine output and oxygen levels (5) time on ventilator support (6) ICU stay
      and (7) hospital stay. Heart tissue will be collected during surgery to determine how
      erythropoietin protects heart cells.

      Statistical tests including ANOVA will test for similarities and differences among the groups
      on the measures of protection from injury.

      Note - the study design was edited after the FDA released a warning about the use of
      erythropoietin. Only acyanotic patients were recruited therefore only 2 study groups are
      included.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate patient enrollment
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Markers of Heart Damage</measure>
    <time_frame>4 postoperative time points up to 48 hours</time_frame>
    <description>Troponin I levels (ng/ml) measured at 4 time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical Markers of Neuron Damage</measure>
    <time_frame>4 postoperative time points</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiographic Assessment of Heart Function</measure>
    <time_frame>24 hours postop</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inotropic Support</measure>
    <time_frame>24 and 48 hours post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospitalization</measure>
    <time_frame>At hospital discharge, up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Congenital Heart Defect</condition>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>acyanotic placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acyanotic erythropoietin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acyanotic erythropoietin</intervention_name>
    <description>Single dose IV push</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acyanotic placebo</intervention_name>
    <description>Single dose IV push</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6 weeks to 18 years

          -  Requiring open heart surgery for congenital heart defect -Parents able to speak
             English and document informed consent -

        Exclusion Criteria:

          -  Received erythropoietin within past 30 days

          -  Previous adverse reaction to erythropoietin or to albumin

          -  History of neurological disorder -Laboratory evidence of kidney or liver dysfunction -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Zangwill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital and Health System Foundation, Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Baker, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shi Y, Rafiee P, Su J, Pritchard KA Jr, Tweddell JS, Baker JE. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol. 2004 May;99(3):173-82. Epub 2004 Jan 29. Erratum in: Basic Res Cardiol. 2004 May;99(3):239.</citation>
    <PMID>15088102</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 22, 2007</study_first_submitted>
  <study_first_submitted_qc>March 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2007</study_first_posted>
  <results_first_submitted>March 21, 2013</results_first_submitted>
  <results_first_submitted_qc>June 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2013</results_first_posted>
  <last_update_submitted>October 11, 2018</last_update_submitted>
  <last_update_submitted_qc>October 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>Congenital heart surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acyanotic Placebo</title>
          <description>Children requiring cardiac surgery with cardiopulmonary bypass with baseline saturations greater than 88% _ Received placebo</description>
        </group>
        <group group_id="P2">
          <title>Acyanotic Study Drug</title>
          <description>Children requiring cardiac surgery with cardiopulmonary bypass with baseline saturations greater than 88% - Received study drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acyanotic Placebo</title>
          <description>Children requiring cardiac surgery with cardiopulmonary bypass with baseline saturations greater than 88% _ Received placebo</description>
        </group>
        <group group_id="B2">
          <title>Acyanotic Study Drug</title>
          <description>Children requiring cardiac surgery with cardiopulmonary bypass with baseline saturations greater than 88% - Received study drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="1.2"/>
                    <measurement group_id="B2" value="12.9" spread="4.5"/>
                    <measurement group_id="B3" value="9.6" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemical Markers of Heart Damage</title>
        <description>Troponin I levels (ng/ml) measured at 4 time points</description>
        <time_frame>4 postoperative time points up to 48 hours</time_frame>
        <population>Analysis was limited to descriptive statistics due to low enrollment and study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyanotic Placebo</title>
            <description>Children requiring cardiac surgery with cardiopulmonary bypass with baseline saturations greater than 88% _ Received placebo</description>
          </group>
          <group group_id="O2">
            <title>Acyanotic Study Drug</title>
            <description>Children requiring cardiac surgery with cardiopulmonary bypass with baseline saturations greater than 88% - Received study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Markers of Heart Damage</title>
          <description>Troponin I levels (ng/ml) measured at 4 time points</description>
          <population>Analysis was limited to descriptive statistics due to low enrollment and study closure.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>60 minutes post bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="12.2"/>
                    <measurement group_id="O2" value="12.3" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hrs post bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="8.6"/>
                    <measurement group_id="O2" value="15" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hrs post bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="6.2"/>
                    <measurement group_id="O2" value="10.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hrs post bypass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.9"/>
                    <measurement group_id="O2" value="5.2" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemical Markers of Neuron Damage</title>
        <time_frame>4 postoperative time points</time_frame>
        <population>There were 43 samples taken from the 9 subjects but no analysis was performed - the laboratory did not set up the assay to run the samples because the study did not have enough subjects to achieve statistical power.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyanotic Placebo</title>
            <description>acyanotic placebo
acyanotic placebo: Single dose IV push</description>
          </group>
          <group group_id="O2">
            <title>Acyanotic Erythropoietin</title>
            <description>acyanotic erythropoietin
acyanotic erythropoietin: Single dose IV push</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Markers of Neuron Damage</title>
          <population>There were 43 samples taken from the 9 subjects but no analysis was performed - the laboratory did not set up the assay to run the samples because the study did not have enough subjects to achieve statistical power.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Echocardiographic Assessment of Heart Function</title>
        <time_frame>24 hours postop</time_frame>
        <population>These data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyanotic Placebo</title>
            <description>acyanotic placebo
acyanotic placebo: Single dose IV push</description>
          </group>
          <group group_id="O2">
            <title>Acyanotic Erythropoietin</title>
            <description>acyanotic erythropoietin
acyanotic erythropoietin: Single dose IV push</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Assessment of Heart Function</title>
          <population>These data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inotropic Support</title>
        <time_frame>24 and 48 hours post operative</time_frame>
        <population>These data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Acyanotic Placebo</title>
            <description>acyanotic placebo
acyanotic placebo: Single dose IV push</description>
          </group>
          <group group_id="O2">
            <title>Acyanotic Erythropoietin</title>
            <description>acyanotic erythropoietin
acyanotic erythropoietin: Single dose IV push</description>
          </group>
        </group_list>
        <measure>
          <title>Inotropic Support</title>
          <population>These data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospitalization</title>
        <time_frame>At hospital discharge, up to 30 days</time_frame>
        <population>Analysis was limited to descriptive statistics due to low enrollment and study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyanotic Placebo</title>
            <description>Children requiring cardiac surgery with cardiopulmonary bypass with baseline saturations greater than 88% _ Received placebo</description>
          </group>
          <group group_id="O2">
            <title>Acyanotic Study Drug</title>
            <description>Children requiring cardiac surgery with cardiopulmonary bypass with baseline saturations greater than 88% - Received study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospitalization</title>
          <population>Analysis was limited to descriptive statistics due to low enrollment and study closure.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="1.2"/>
                    <measurement group_id="O2" value="6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acyanotic Placebo</title>
          <description>Children requiring cardiac surgery with cardiopulmonary bypass with baseline saturations greater than 88% _ Received placebo</description>
        </group>
        <group group_id="E2">
          <title>Acyanotic Study Drug</title>
          <description>Children requiring cardiac surgery with cardiopulmonary bypass with baseline saturations greater than 88% - Received study drug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>A brief post -op seizure occurred in a study participant who received placebo. There were no clinical sequelae.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Analysis was limited to descriptive statistics due to low enrollment and study closure. The number of participants fell far short of study goals and the study was terminated prematurely due to inadequate enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Steven Zangwill</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>414-266-2380</phone>
      <email>szangwill@chw.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

